Top-line results of PARADIGM trial into PrimeC expected by year’s end
NeuroSense Therapeutics is planning to soon announce top-line safety and efficacy results from its PARADIGM trial, which is…
Articles by Andrea Lobo, PhD
Survey offers look at life, treatment priorities of those living with ALS
People with amyotrophic lateral sclerosis (ALS) report significant changes in lifestyle after their diagnosis, but still have an acceptable…
FDA names CB03, aiming to protect neurons, an orphan drug for ALS
The U.S. Food and Drug Administration (FDA) has given orphan drug designation to CB03, Zhimeng Biopharma’s small molecule…
BrainStorm drops FDA application for NurOwn
BrainStorm Cell Therapeutics is withdrawing the application requesting U.S. approval of its cell-based therapy NurOwn for the treatment…
PrimeC, potential ALS therapy, earns patents in Europe, Japan, Israel
NeuroSense Therapeutics has received key patents in Europe, Japan, and Israel covering the use of PrimeC, its investigational,…
Aruna Bio’s AB126 eased inflammation in ALS mouse model
Aruna Bio‘s investigational therapy AB126 significantly eased inflammation in the spinal cord and extended survival in a mouse…
FDA clears first-in-human clinical trial of AKV9 in healthy volunteers
Akava Therapeutics will soon launch a Phase 1 clinical trial to test AKV9, its investigational therapy for amyotrophic…
Opioid use greater for ALS patients on noninvasive ventilation: Study
People with amyotrophic lateral sclerosis (ALS) who require noninvasive ventilation in later disease stages use significantly higher opioid doses…
Cystatin C may be biomarker to predict survival, disease progression
Elevated blood levels of the Cystatin C protein are significantly associated with faster disease progression and shorter survival in people…
Coya to meet with FDA about a Phase 2 trial of COYA 302 for ALS
Coya Therapeutics is planning to file a request with the U.S. Food and Drug Administration (FDA) to continue testing…